CN115379827A - 苯达莫司汀组合物及其用途 - Google Patents

苯达莫司汀组合物及其用途 Download PDF

Info

Publication number
CN115379827A
CN115379827A CN202080099405.9A CN202080099405A CN115379827A CN 115379827 A CN115379827 A CN 115379827A CN 202080099405 A CN202080099405 A CN 202080099405A CN 115379827 A CN115379827 A CN 115379827A
Authority
CN
China
Prior art keywords
cyclodextrin
bendamustine
glucose
composition
sodium chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080099405.9A
Other languages
English (en)
Inventor
井玥
颜青
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bica Biotechnology Guangzhou Co ltd
Original Assignee
Bica Biotechnology Guangzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bica Biotechnology Guangzhou Co ltd filed Critical Bica Biotechnology Guangzhou Co ltd
Publication of CN115379827A publication Critical patent/CN115379827A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

苯达莫司汀组合物及其用途，该组合物包含以下组分：a)苯达莫司汀或其盐，b)环糊精，c)任选的稳定剂，其中所述稳定剂选自含氯元素的无机物或有机物、硫辛酸、硫代甘油、聚乙烯吡咯烷酮以及它们的任意组合，并且其中所述苯达莫司汀或其盐与所述环糊精的质量比为1∶5～1∶100。并提供了一种使用所述组合物预防或治疗癌症的方法以及所述组合物在制备用于治疗癌症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080099405.9A 2020-04-09 2020-04-09 苯达莫司汀组合物及其用途 Pending CN115379827A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/084038 WO2021203377A1 (zh) 2020-04-09 2020-04-09 苯达莫司汀组合物及其用途

Publications (1)

Publication Number Publication Date
CN115379827A true CN115379827A (zh) 2022-11-22

Family

ID=78022443

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080099405.9A Pending CN115379827A (zh) 2020-04-09 2020-04-09 苯达莫司汀组合物及其用途

Country Status (6)

Country Link
US (1) US20220304983A1 (zh)
EP (1) EP4134068A4 (zh)
JP (1) JP2023529033A (zh)
CN (1) CN115379827A (zh)
CA (1) CA3145107A1 (zh)
WO (1) WO2021203377A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240148696A1 (en) * 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition
CN115770248B (zh) * 2022-12-07 2023-08-04 郑州大学第一附属医院 一种盐酸伊伐布雷定制剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101606934A (zh) * 2009-07-27 2009-12-23 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物
CN102421451A (zh) * 2009-02-25 2012-04-18 休普拉特克药品有限公司 苯达莫司汀环多糖组合物
CN103228296A (zh) * 2010-07-19 2013-07-31 速沛达制药公司 苯达莫司汀阴离子-阳离子型环聚糖组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102450975B1 (ko) * 2017-10-05 2022-10-07 튜브 파마수티칼스 게엠베하 경구 벤다무스틴 제형
CN111557904A (zh) * 2020-04-09 2020-08-21 比卡生物科技（广州）有限公司 苯达莫司汀组合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102421451A (zh) * 2009-02-25 2012-04-18 休普拉特克药品有限公司 苯达莫司汀环多糖组合物
CN101606934A (zh) * 2009-07-27 2009-12-23 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物
CN103228296A (zh) * 2010-07-19 2013-07-31 速沛达制药公司 苯达莫司汀阴离子-阳离子型环聚糖组合物

Also Published As

Publication number Publication date
CA3145107A1 (en) 2021-10-14
EP4134068A1 (en) 2023-02-15
US20220304983A1 (en) 2022-09-29
WO2021203377A1 (zh) 2021-10-14
EP4134068A4 (en) 2024-02-07
JP2023529033A (ja) 2023-07-07

Similar Documents

Publication Publication Date Title
CN111093674B (zh) 一种磺酰脲类药物的药物组合物及其制备方法
JP6407221B2 (ja) 抗菌性組成物
CN115379827A (zh) 苯达莫司汀组合物及其用途
MX2008014948A (es) Composicion farmaceutica estable que contiene docetaxel, y un metodo para fabricarla.
NO329382B1 (no) Fremgangsmate for fremstilling av umiddelbart loselige, faste produkter, selve produktet samt anvendelse derav og fremgangsmate for forebyggelse av selvaggregering og prematur utfelling av et taksoid
EP2720723A1 (en) Stabilized voriconazole composition
EP2827862A1 (en) Formulations of bendamustine
JP2002507582A (ja) 鉄欠乏症の予防または治療のための治療組成物の成分として用いる鉄−デキストラン化合物、前記鉄−デキストラン化合物の製造法、および非経口投与可能な治療組成物の製造のための前記化合物の使用
CN108366963A (zh) 包含丹曲林的水性组合物
CN101744778A (zh) 一种注射用伏立康唑磷酸酯及其制备方法
CN111557904A (zh) 苯达莫司汀组合物及其用途
JPS59152320A (ja) 水性製剤
WO2016110225A1 (zh) 一种磺酰胺类药物组合物
CN102688183B (zh) 一种稳定的盐酸莫西沙星注射剂
USRE24642E (en) Therapeutic preparations of iron
CN104940135A (zh) 一种氟康唑注射液及其制备方法
EP3687498A1 (en) Parenteral formulation comprising siponimod
CN115746408A (zh) 用于腹膜透析的新颖的葡萄糖聚合物
WO2013026694A1 (en) Pharmaceutical compositions comprising voriconazole
CN109078001A (zh) 一种新型万古霉素纳米脂质体组合物及其制备方法
EP2253329B1 (en) Ibuprofen lysinate oral suspension
JP7267640B2 (ja) 希釈安定性に優れたテニポシド注射用溶液及びその調製方法
WO2024117070A1 (ja) ナフタレン誘導体の眼科疾患用治療薬
CN114617843A (zh) 一种米力农注射液及其制备方法和应用
WO2022147743A1 (en) Pharmaceutical compositions of chemotherapeutic agents based on beta-substituted beta-amino acid derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075585

Country of ref document: HK